基质
一致性
间质细胞
转移
免疫组织化学
医学
肿瘤进展
亚型
病理
转录组
原发性肿瘤
癌症研究
癌症
肿瘤科
生物
内科学
基因表达
基因
生物化学
计算机科学
程序设计语言
作者
Alexander M. G. Cox,Niklas Klümper,Johannes Stein,Danijel Sikic,Johannes Breyer,Christian Bolenz,Florian Roghmann,Philipp Erben,Ralph M. Wirtz,Bernd Wullich,Manuel Ritter,Michael Hölzel,Kristina Schwamborn,Thomas Horn,Jürgen E. Gschwend,Arndt Hartmann,Wilko Weichert,Franziska Erlmeier,Markus Eckstein
标识
DOI:10.1016/j.eururo.2023.03.020
摘要
Urothelial cancer (UC) care is moving toward precision oncology. For tumor biology-driven treatment of metastatic UC (mUC), molecular subtypes play a crucial role. However, it is not known whether subtypes change during metastatic evolution. To address this, we analyzed a UC progression cohort (N = 154 patients) with 138 matched primary tumors (PRIM) and synchronous or metachronous distant metastasis (MET) by immunohistochemistry, and mRNA sequencing in a subgroup of 20 matched pairs. Protein-based tumor cell subtypes and histomorphology remained stable during metastatic progression (concordance: 94%, 95% confidence interval [CI] 88-97%). In comparison, transcriptome-based molecular consensus subtypes exhibited higher heterogeneity between PRIM and MET (concordance: 45%, 95% CI 23-69%), with switches particularly occurring between luminal and stroma-rich tumors. Of note, all tumors classified as stroma rich showed luminal tumor cell differentiation. By an in-depth analysis, we found a negative correlation of luminal gene and protein expression with increasing desmoplastic stroma content, suggesting that luminal tumor cell differentiation of "stroma-rich tumors" is superimposed by gene expression signals stemming from the stromal compartment. Immunohistochemistry allows tumor cell subtyping into luminal, basal, or neuroendocrine classes that remain stable during metastatic progression. These findings expand our biological understanding of UC MET and have implications for future subtype-stratified clinical trials in patients with mUC. PATIENT SUMMARY: Urothelial carcinomas (UCs) occur in different appearances, the so-called molecular subtypes. These molecular subtypes will gain importance for the therapy of metastatic UCs in the future. We could demonstrate that the subtype remains stable during metastasis, which is highly relevant for future studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI